Precision's Messerschmidt Talks Immunotherapy with ASCO Post


Precision Oncology Chief Medical Officer Gerald Messerschmidt sits down to talk with ASCO Post‘s Ronald Piana regarding the future of immunotherapy. Dr. Messerschmidt touches on a number of topics, including immune surveillance, checkpoint inhibitors, cancer cell cloaking and the future of therapy combinations.

To read the complete article, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.